<DOC>
	<DOCNO>NCT01340547</DOCNO>
	<brief_summary>This open-label study palifosfamide-tris administer intravenously Days 1 , 2 , 3 21-day cycle subject advance solid tumor . Enrolled subject receive placebo-control infusion Day -1 commence palifosfamide-tris study treatment 24 hour later Day 1 . Time-matched , intensive ECG monitoring occur follow placebo palifosfamide-tris infusion Days -1 , 1 , 2 , 3 8 . Generation ECG data study analysis perform blinded fashion central ECG laboratory . Blood urine sample characterize pharmacokinetics palifosfamide-tris perform Days 1 8 Cycle 1 .</brief_summary>
	<brief_title>Effect QTc , Pharmacokinetics , Safety , Preliminary Efficacy Single-agent Palifosfamide-tris Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female subject , age ≥ 18 year , provide write informed consent prior complete study specific procedure . 2 . Histologically cytologically confirm solid tumor progress follow available standard therapy standard therapy exist . 3 . Measurable nonmeasurable disease RECIST version 1.1 4 . Must recover toxic effect prior cancer treatment ≤ Grade1per CTCAE v4.0 , exception alopecia . 5 . ECOG Performance Status 0 1 . 6 . Adequate bone marrow , liver , renal function , assess follow laboratory requirement : 1 . Hemoglobin ≥9.0 g/dL . 2 . Absolute neutrophil count ( ANC ) ≥1,500/uL . 3 . Platelet count ≥100,000/uL . 4 . Total bilirubin ≤1.5 x upper limit normal ( ULN ) 5 . ALT AST ≤2.5 x ULN . For subject document liver metastasis , ALT AST ≤5×ULN . 6. International Normalized Ratio ( INR ) activate partial thromboplastin time [ PTT ] &lt; 1.5 x ULN , therapeutically anticoagulated . Subjects therapeutically anticoagulated agent Coumadin ( warfarin sodium ) subcutaneous heparin may include provide prior evidence underlie abnormality coagulation parameter , screen test result appropriate therapeutic range , anticoagulation regimen stable closely monitor . 7 . Estimated glomerular filtration rate ( eGRF ) ≥60 mL/minute/1.73 m2 . 7 . Male female subject must agree use highly reliable method birth control ( expect failure rate le 5 % per year ) screen visit 28 day last dose study drug . 1 . Subjects receive prior chemotherapy , radiation therapy investigational agent within 28 day prior first dose study drug . 2 . Unstable clinically significant concurrent medical condition would , opinion investigator , jeopardize safety subject and/or compliance protocol . Examples include , limited , unstable angina , congestive heart failure , recent ( within 2 month screen ) myocardial infarction , ongoing maintenance therapy lifethreatening ventricular arrhythmia , uncontrolled asthma , HIV/AIDS without adequate antiviral therapy , evidence hepatic pathology due consistent infection chronic hepatitis virus , uncontrolled major seizure disorder , electrolyte imbalance . 3 . Presence , history illness injury urinary tract ( renal postrenal ) may make subject susceptible acute renal insufficiency case potential renal adverse event . Types injury illness might include history polycystic renal disease , nephrectomy , renal transplant , acute chronic renal failure . 4 . Active infection require systemic antibacterial , antifungal , antiviral therapy within 2 week first dose study drug . Subjects HIV effective antiviral therapy subject chronic herpes infection use intermittent suppressive antiviral therapy viral outbreak may include . 5 . Major surgery within 4 week prior start treatment . 6 . Documented symptomatic brain metastasis . Screening brain lesion CT MRI require potential subject ; however , neurological sign symptom consistent brain metastasis , brain CT MRI perform clinically indicate . 7 . Currently pregnant nursing . 8 . Subjects implantable pacemaker automatic implantable cardioverter defibrillator . 9 . Conditions make screen ECG repolarization difficult interpret , show significant abnormality . This include , limited : high degree AV block , pacemaker , atrial fibrillation flutter , prolong QTc &gt; 500ms repeat measurement ( e.g. , 2 3 ECGs ) , bradycardia ( define ≤ 50 beats/minute ) . 10 . Subjects receive medication prolong QT interval risk cause Torsades de Pointes time period begin 1 week prior Intensive ECG monitoring period ( i.e. , Cycle 1 , Day 8 Day 8 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Safety</keyword>
	<keyword>PK</keyword>
	<keyword>ECG QTc</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Palifosfamide-tris</keyword>
	<keyword>non-randomized</keyword>
</DOC>